Want to join the conversation?
$AMGN said that data from Phase 2 trial evaluating BLINCYTO showed that BLINCYTO achieved 36% remission in a high-risk subpopulation of patients with relapsed Philadelphia chromosome-positive B-precursor ALL and induced a CR/CRh rate of 45% of BLINCYTO's efficacy in a subset of patients with relapsed Philadelphia chromosome-negative ALL.
Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$
$CRM on the pop today.. big bubble.
Slumping and down the drain... $HDSN. Flush out your holdings !
$KITE I am loving this one... really flying like a kite today :-)